KemPharm IPO Raises $56M After Pricing Below Range
Late-stage biotech company KemPharm Inc. stumbled in its initial public offering Wednesday, raising $56 million after pricing shares below their expected range but selling additional shares to hit its target raise...To view the full article, register now.
Already a subscriber? Click here to view full article